Skip to main content
Journal cover image

Aripiprazole: pharmacology, efficacy, safety and tolerability.

Publication ,  Journal Article
Kinghorn, WA; McEvoy, JP
Published in: Expert Rev Neurother
May 2005

Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Aripiprazole is generally well tolerated relative to other antipsychotic medications, although commonly reported side effects include worsening extrapyramidal symptoms and motoric activation similar to akathisia. Further studies and postmarketing data will be helpful in providing additional information about the comparative safety, efficacy and tolerability of aripiprazole.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Neurother

DOI

EISSN

1744-8360

Publication Date

May 2005

Volume

5

Issue

3

Start / End Page

297 / 307

Location

England

Related Subject Headings

  • Schizophrenia
  • Quinolones
  • Piperazines
  • Neurology & Neurosurgery
  • Humans
  • Bipolar Disorder
  • Aripiprazole
  • Antipsychotic Agents
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kinghorn, W. A., & McEvoy, J. P. (2005). Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother, 5(3), 297–307. https://doi.org/10.1586/14737175.5.3.297
Kinghorn, Warren A., and Joseph P. McEvoy. “Aripiprazole: pharmacology, efficacy, safety and tolerability.Expert Rev Neurother 5, no. 3 (May 2005): 297–307. https://doi.org/10.1586/14737175.5.3.297.
Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother. 2005 May;5(3):297–307.
Kinghorn, Warren A., and Joseph P. McEvoy. “Aripiprazole: pharmacology, efficacy, safety and tolerability.Expert Rev Neurother, vol. 5, no. 3, May 2005, pp. 297–307. Pubmed, doi:10.1586/14737175.5.3.297.
Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother. 2005 May;5(3):297–307.
Journal cover image

Published In

Expert Rev Neurother

DOI

EISSN

1744-8360

Publication Date

May 2005

Volume

5

Issue

3

Start / End Page

297 / 307

Location

England

Related Subject Headings

  • Schizophrenia
  • Quinolones
  • Piperazines
  • Neurology & Neurosurgery
  • Humans
  • Bipolar Disorder
  • Aripiprazole
  • Antipsychotic Agents
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences